
    
      The FlexNav European Union (EU) study will be conducted as a prospective, multi-center,
      single-arm investigational study.

      High or extreme risk patients with symptomatic, severe native aortic stenosis who are
      determined by an independent subject selection committee to meet eligibility criteria for
      Porticoâ„¢ Transcatheter Aortic Heart Valve implantation via a transfemoral access approach
      will undergo a Portico valve implant using the next-generation FlexNav Delivery System.

      Subject data will be collected at screening, baseline, pre-procedure, peri-procedure,
      post-procedure, discharge, 30 days, 6 months and 1-year from the index procedure.
    
  